LONGJUMEAU, France, June 8, 2021 /PRNewswire/ — The French biotech TargEDys specialised in breakthrough microbiome-based options proclaims the publication of its examine performed in 230 chubby adults supplemented for 12 weeks, confirming the efficacy of the precision probiotic Hafnia alvei HA4597® to enhance weight reduction, hip circumference discount and metabolic parameters because of the motion of the probiotic and its postbiotic ClpB on feeling of fullness.
Mechanistic and preclinical research confirmed Hafnia alvei is ready to produce Caseinolytic peptidase B, a protein mimicking the hormone of satiety alpha-MSH, and to cut back meals consumption in murine fashions of weight problems. These new outcomes verify the efficacy of this PreciBiomic™ pressure in supporting feeling of fullness and weight reduction in chubby topics, in addition to lowering hip circumference and glycemia.
With a median of three,6% weight reduction in 12 weeks within the probiotic group, Hafnia alvei is dramatically simpler than another probiotic studied in weight administration, and this degree of impression fills the hole between the sectors of meals dietary supplements and medicines. It additionally drives innovation within the probiotics subject, shifting the strategy to precision probiotics, with enhanced efficacy because of the exact understanding of the molecular mechanism of motion.
Hafnia alvei may be discovered within the merchandise EnteroSatys® and Satylia® in France, Portugal, Italy and Slovenia, and TargEDys is on the lookout for distribution companions to make this breakthrough answer for the prevention of weight problems accessible to customers worldwide.
Grégory Lambert, CEO of TargEDys, declares:
“This shall be a game-changer within the sector of weight administration, with lastly an answer that meets customers expectations when it comes to security and naturality, whereas additionally bringing an actual, demonstrated efficacy based mostly on molecular mimicry and the biochemical regulation of urge for food.”
About TargEDys®
TargEDys® is a commercial-stage French biotech specialised within the growth of nutraceutical options for the management of urge for food by way of microbiome interventions. The firm is the fruit of 15 years of analysis on the microbiota performed inside educational laboratories. The firm developed and began the commercialization of its first product based mostly on the PreciBiomic pressure Hafnia alvei HA4597™ and develops a product portfolio specializing in chubby, undernutrition and psychological well being, all based mostly on the idea of precibiomic strains backed by a molecular mechanism of motion and in vivo research.
More data at www.targedys.com
Contact: Arnaud Faure & Nina Vinot; [email protected]
SOURCE TargEDys
